[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362200-105":59,"doc-detail-362200-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tigit-disruption-rescues-the-antitumor-activity-of-low-avidity-tcr-engineered-t-cells-by-increasing-tcr-signal-strength","TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength","","TIGIT disruption rescues antitumor activity of low-avidity TCR-engineered T cells in pancreatic ductal adenocarcinoma by boosting intracellular signaling from weak TCR engagement. Using TIGIT knockout via base editing, the study enhances cytoskeletal rearrangements, increases T cell avidity, stabilizes the immunological synapse, and enables robust degranulation comparable to high-avidity cells. In male mice, TIGIT-disrupted low-avidity T cells show potent and durable in vivo anti-tumor capacity. Results support TIGIT knockout as a strategy to improve low-avidity engineered T cell function for PDAC and other solid malignancies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tigit-disruption-rescues-the-antitumor-activity-of-low-avidity-tcr-engineered-t-cells-by-increasing-tcr-signal-strength/362200/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tigit-disruption-rescues-the-antitumor-activity-of-low-avidity-tcr-engineered-t-cells-by-increasing-tcr-signal-strength/362200.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are low-avidity T cells a problem for adoptive T cell therapy in solid tumors?","Question",{"text":112,"@type":113},"Low-avidity T cells are harder to obtain because highly reactive TCRs are scarce, and low-avidity populations generate insufficient immune responses, limiting tumor shrinkage.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does TIGIT disruption improve the function of low-avidity T cells?",{"text":117,"@type":113},"Knocking out TIGIT via base editing strengthens intracellular signaling from weak TCR engagement, promotes cytoskeletal rearrangements, increases T cell avidity, and stabilizes the immunological synapse.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence shows TIGIT disruption can enhance anti-tumor activity in vivo?",{"text":121,"@type":113},"TIGIT-disrupted low-avidity T cells induce robust degranulation and demonstrate potent, durable anti-tumor capacity in male mice against pancreatic cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362200,1790313570,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Article [https://doi.org/10.1038/s41467-025-67263-w](https://doi.org/10.1038/s41467-025-67263-w)  \nTIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength  \nReceived: 15 April 2025  \n\n| Accepted: 26 November 2025 |\n| --- |\n| |\n| Check for updates |\n\nMartina Spiga 1,15, Alessia Potenza 1,15, Zulma Magnani1, Stefano Beretta2, Barbara Camisa1, Laura Conte1, Alessia Airaghi1, Neda Mohammadi1,  \nLaura Perani 3, Claudio Doglioni 4,5, Maurilio Ponzoni 4,5,  \nFrancesca Sanvito 4, Chiara Balestrieri 1,6, Lucia Sergi Sergi1,  \nOronza A. Botrugno 5,7, Giulio Giovannoni7, Giovanni Tonon 5,6,7,  \nDanilo Abbati 1, Chiara Iozzi1, Maximilian Reichert 8, Hana Algul9,  \nArianna Pocaterra10, Martina Fiumara 2, Samuele Ferrari 2,5, Alessia Ugolini1, Alice Grometto1, Giulia Di Lullo1, Giovanni Sitia 5,11, Giulio Belﬁori12,  \nMaria Pia Protti13, Renato Ostuni 2,5, Anna Mondino10, Michele Reni5,14, Stefano Crippa5,12, Massimo Falconi 5,12, Luigi Naldini 2,5,  \nEliana Ruggiero 1,16 & Chiara Bonini 1,5,16   \nT-cell avidity is a major determinant of Adoptive T cell therapy (ACT) efﬁcacy for cancer treatment. However, high-avidity tumor-speciﬁc T cells can rarely be isolated from cancer patients, highlighting the need for strategies to enhance the cytotoxic capacity of low-avidity cells. Here, we rescue the antitumor functions of low-avidity T cells against pancreatic ductal adenocarcinoma (PDAC) by knocking-out TIGIT, a key inhibitory molecule expressed on exhausted CD8+ T cells inﬁltrating gastrointestinal tumors. We uncover that TIGIT disruption by base editing boosts the intracellular signal transduction derived from a weak T cell receptor (TCR) engagement enforcing cytoskeletal rearrangements, thus increasing T cell avidity and stabilizing the immunological synapse. Accordingly, TIGIT disruption enables low-avidity T cells to exert robust degranulation, comparable to that of high-avidity T cells, and potent and durable anti-tumor capacity in vivo in male mice. These results highlight TIGIT knockout as a potential strategy to enhance low-avidity T cell function and broaden the repertoire of TCR engineered T cells in the treatment of pancreatic cancer and other solid malignancies.  \nWhile Adoptive T Cell Therapy (ACT) revolutionized the treatment of hematological malignancies, its efﬁcacy in solid tumors remains suboptimal1. A key limitation is the identiﬁcation of functional TCRsspeciﬁc for relevant tumor antigens, especially in tumors with low mutational burden. Several protocols have been now developed to isolate tumor-speciﬁc TCRs from either patients or healthy donors;  \nhowever, clones that are highly reactive against tumor-associated antigens (TAAs), which are self-antigens highly overexpressed by cancer cells and shared across patients, are scarce. This heightens the probability ofisolating low-avidity T cell populations, demonstrated tobe less effective in building a sufﬁcient immune response for promoting tumor shrinkage2,3. Hence, innovative strategies to enhance the  \nA full list of afﬁliations appears at the end of the paper. e-mail: [bonini.chiara@hsr.it](bonini.chiara@hsr.it)  \nfunctionality of low-avidity T cells, are required to broaden the applicability ofT cell transfer and to deliver safe and effective products to patients diagnosed with solid tumors. Among these, pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related death within the next 10 years, surpassing colorectal cancer4. Advanced patients represent the majority (80-85%) of PDAC diagnoses, precipitating the 5-year survival rate to 8%5, and their outcome is poorly impacted by conventional treatments or immunotherapy with immune checkpoint blockade6. This is due to the intrinsic aggressiveness of this tumor entity, sustained by networks of malignant and non-malignant cells that build strong immunosuppressive interactions and an immune-excluded tumor microenviron","cbCaisGV7zZECwUQ","https://ap.wps.com/l/cbCaisGV7zZECwUQ","pdf",2792955,"English","# Background and rationale\n## Adoptive T cell therapy challenges in solid tumors\n## Role of TIGIT in exhausted CD8+ T cells and PDAC\n# Experimental approach\n## Base editing knockout of TIGIT\n# Findings and implications\n## Restoring signaling, avidity, and immunological synapse stability\n## Anti-tumor effects in vivo","[{\"question\":\"Why are low-avidity T cells a problem for adoptive T cell therapy in solid tumors?\",\"answer\":\"Low-avidity T cells are harder to obtain because highly reactive TCRs are scarce, and low-avidity populations generate insufficient immune responses, limiting tumor shrinkage.\"},{\"question\":\"How does TIGIT disruption improve the function of low-avidity T cells?\",\"answer\":\"Knocking out TIGIT via base editing strengthens intracellular signaling from weak TCR engagement, promotes cytoskeletal rearrangements, increases T cell avidity, and stabilizes the immunological synapse.\"},{\"question\":\"What evidence shows TIGIT disruption can enhance anti-tumor activity in vivo?\",\"answer\":\"TIGIT-disrupted low-avidity T cells induce robust degranulation and demonstrate potent, durable anti-tumor capacity in male mice against pancreatic cancer.\"}]","TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength | PDF",1790146772,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c26fa9471f6af8abeb628e8887d2a29c.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/013c526deb34cdafd97f72f8fde1fb5b.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f970c15b3a8133d1fb9daa901f852b8b.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b33823e90ca4340c5808175146da3ffb.webp",980,1301]